Transcutaneous Imiquimod Combined With Anti‐Programmed Cell Death‐1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell Carcinoma

Transcutaneous Imiquimod Combined With Anti‐Programmed Cell Death‐1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell Carcinoma

ABSTRACT Purpose Imiquimod (IQM), an imidazoquinoline derivative, is an immunomodulator that activates an adaptive immune response. IQM is applied topically for genital warts and actinic keratosis. Programmed cell death‐1 (PD‐1) suppresses activated T cells by binding to programmed cell death‐ligand...

Full description

Saved in:
Bibliographic Details
Main Authors: Takashi Karashima, Toshihiro Komatsu, Shinkuro Yamamoto, Kaya Atagi, Hatsune Hashida, Hideo Fukuhara, Kenji Tamura, Shingo Ashida, Taro Shuin, Keiko Udaka, Takahiro Shimizu, Motoaki Saito, Nobutaka Shimizu, Keiji Inoue
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Cancer Medicine
Subjects:
IgG
imiquimod
immune checkpoint inhibitor
programmed cell death‐1
renal cell carcinoma
spleen
Online Access:https://doi.org/10.1002/cam4.70966
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70966

Similar Items